

Preauthorization Statistics for Arkansas Plans with Wellfleet Rx/ESI

Q3 2022

		Treatment	
Provider Specialty Type	Drug	Description	Decision
INTERNAL MEDICINE	Winlevi 1% cream	Acne Vulgaris	Denied

Q2 2022

No Preauthorization Requests for Arkansas plans during Q2 2022 (4/1/22-6/30/22)

Q1 2022

No Preauthorization Requests for Arkansas plans during Q1 2022 (1/1/22-3/31/22)

Q4 2021

<u>Q. 2021</u>			
		Treatment	
Provider Specialty Type	Drug	Description	Decision
		Immune	
		thrombocytopenic	
INTERNAL MEDICINE	Promacta 75mg Tablet	purpura	Approval

Q3 2021

-4			
		Treatment	
Provider Specialty Type	Drug	Description	Decision
		Immune	
		thrombocytopenic	
INTERNAL MEDICINE	Promacta 75mg Tablet	purpura	Approval

Q2 2021

No Preauthorization Requests for Arkansas plans during Q2 2021 (4/1/21-6/30/21)

Q1 2021

No Preauthorization Requests for Arkansas plans during Q1 2021 (1/1/21-3/31/21)

Q4 2020

No Preauthorization Requests for Arkansas plans during Q4 2020 (10/1/20-12/31/20)

Q3 2020



		Treatment	
Provider Specialty Type	Drug	Description	Decision
DERMOTOLOGY	Cosentyx Pen (2 pen) 150mg/ml	Psoriatic Arthritis	Approval